Summary of Key Points from Conference Call Industry Overview - The conference call discusses the gastrointestinal endoscopy industry, specifically focusing on the upcoming launch of the X1 endoscope by Olympus, which holds over 70% market share in the global soft endoscope market [1][1]. Core Insights and Arguments - The launch of the X1 endoscope is anticipated to create a new growth cycle in the gastrointestinal endoscopy sector, with hospitals potentially delaying procurement of gastrointestinal endoscopes until the X1 is available [1][1]. - After the X1's launch, hospitals are expected to engage in concentrated purchasing, leading to a noticeable increase in quarterly revenue growth year-on-year within a year of the product's release [1][1]. - The domestic soft endoscope market is expected to face pressure in 2024 due to reduced bidding scale from policy factors and the fact that only the main unit of the X1 has been approved in China, causing some hospitals to postpone their purchases [1][1]. Future Expectations - The X1 endoscope is projected to be launched in China by the end of this year or early next year, which, combined with favorable policy changes and a prolonged destocking period for soft endoscope companies, may lead to a significant release of demand and improvement in company performance [2][2]. - The technological level of domestic soft endoscopes is continuously improving, gaining recognition from high-level domestic hospitals and initial acceptance in overseas markets. This positions domestic manufacturers to benefit from the industry growth driven by the X1 [3][3]. Investment Recommendations - Companies to watch include Aohua Endoscopy and Kaili Medical, which may benefit from the anticipated market changes and growth opportunities [4][4].